NCT03696212 - Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2019

Primary Completion Date

February 15, 2021

Study Completion Date

February 15, 2021

Conditions

Non-small Cell Lung Cancer Adenocarcinoma

Interventions

DRUG

grapiprant and pembrolizumab

Participants will be administered 21-day cycles of oral grapiprant in combination with IV pembrolizumab

Trial Locations (6)

University of Pennsylvania Abramson Cancer Center, Philadelphia

Fox Chase Cancer Center, Philadelphia

Virginia Cancer Specialists, Fairfax

Barbara Ann Karmanos Cancer Institute, Detroit

START Midwest, Grand Rapids

Stanford University Medical Center, Stanford